Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer

Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357

Interpreting the significance of changes in health-related quality-of-life scores.

Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503

ARID1A mutational status in non-small cell lung cancer: from molecular pathology to clinical implications with a focus on the relationships with EGFR

Lecce, C. D., Eccher, S., Simbolo, M., Cocomazzi, A., Piredda, M. L., Caliò, A., Cima, L., Munari, E., Veronese, N., Avancini, A., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108594 · Cited by 3

The efficacy of adding hyperthermia to the treatment of advanced NSCLC patients based on the states of EGFR

Zhou, Y., Zhong, Q., Huang, D., Li, Q., Huang, J. H., Wang, C., Chen, B., Chen, M., Li, Y., & Liu, W. (2022) · Aging · doi:10.18632/aging.204148 · Cited by 3

Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses

Horita, N. (2022) · Cancers · doi:10.3390/cancers15010185 · Cited by 3

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application

Yang, H., Miao, Y., Yu, Z., Wei, M., & Jiao, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1107631 · Cited by 3

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression

Inno, A., Bogina, G. S., Settanni, G., Salgarello, M., Foti, G., Pomari, C., Picece, V., & Gori, S. (2023) · Drug Target Insights · doi:10.33393/dti.2023.2626 · Cited by 3

Stage as the Sole “Biomarker” for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091?

Nagasaka, M., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s433195 · Cited by 3

First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis

Zheng, Z., Fang, L., & Cai, H. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-076383 · Cited by 3

Cost Matters

Guirgis, H. (2023) · Open Access Journal of Cancer & Oncology · doi:10.23880/oajco-16000184 · Cited by 3

Classification of the Tumor Immune Microenvironment Using Machine-Learning-Based CD8 Immunophenotyping As a Potential Biomarker for Immunotherapy and TGF-β Blockade in Nonsmall Cell Lung Cancer

Pomponio, R. J., Wang, H., Bean, S. M., Tang, Q., Trullo, R., Lee, J. S., Demers, B., Khosla, A., Stanford-Moore, A., Guramare, M., et al. (2024) · AI in Precision Oncology · doi:10.1089/aipo.2023.0008 · Cited by 3

Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent Pembrolizumab

Svatoň, M., Knetki‐Wróblewska, M., Tabor, S., Domecky, P., Venclíček, O., Krejčí, J., Drösslerová, M., Hrnčiarik, M., Hricisak, D., Bejčková, A., et al. (2024) · In Vivo · doi:10.21873/invivo.13712 · Cited by 3

Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytotoxic T-lymphocyte-associated Protein-4

Resuli, B., & Kauffmann-Guerrero, D. E. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001106 · Cited by 3

CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma

Park, S. J., Ellison, D. M., Weight, R. M., Homsi, J., Rabinowits, G., Ruiz, E. S., Strasswimmer, J., Simmons, J. D., Panella, T., Quek, R. G. W., et al. (2025) · Future Oncology · doi:10.1080/14796694.2024.2448416 · Cited by 3

Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study

Zhao, D. B., Bi, M., Cheng, X., Wang, S., Cheng, H., Xia, X., Chen, H., Zhang, Y., Hu, Z., Cao, Q., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1494708 · Cited by 3

Anticancer mechanisms and applications based on γδ T cells in cancer immunotherapy

Yang, Q., Na, J., Qin, S., Su, J., Huang, H., & Zhong, L. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104814 · Cited by 3

PD-1/PD-L1 inhibitors monotherapy vs. combination therapy in elderly advanced NSCLC: a real-world study and nomogram for survival prognosis

Mao, Y., Wang, A., Ge, X., Zhai, J., Hu, Y., & Wang, J. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03791-x · Cited by 3

Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naïve patients

Chen, Y., Chang, S., Chang, C., Chang, C.-F., Lai, Y.-C., Wei, Y.-F., & Chen, C. (2021) · BMC Cancer · doi:10.1186/s12885-021-08920-3 · Cited by 3

Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?

Timon-David, É., Perez, C., & Rodallec, A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112326 · Cited by 3

Treatments for brain metastases from EGFR/ALK-negative/unselected NSCLC: A network meta-analysis

Zhang, C., Zhou, W., Zhang, D., Ma, S., Wang, X., Jia, W., Guan, X., & Qian, K. (2023) · Open Medicine · doi:10.1515/med-2022-0574 · Cited by 3

Target Therapy vs the Immune Check Point Inhibitors in Lung Cancer: Costs and Caps Platform

Guirgis, H. M. (2023) · Medical Research Archives · doi:10.18103/mra.v11i2.3641 · Cited by 3

Identification and prognostic analysis of ferroptosis‑related gene HSPA5 to predict the progression of lung squamous cell carcinoma

Guo, D., Feng, Y., Liu, P., Yang, S., Zhao, W., & Li, H. (2024) · Oncology Letters · doi:10.3892/ol.2024.14320 · Cited by 3

Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer

Camerini, A., Mazzoni, F., Scotti, V., Tibaldi, C., Sbrana, A., Calabrò, L., Caliman, E., Ciccone, L. P., Bernardini, L., Graziani, J., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133642 · Cited by 3

Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)

Merle, G., & Addeo, A. (2023) · Praxis · doi:10.1024/1661-8157/a003973 · Cited by 4

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways

Mountzios, G., Banna, G. L., & Rolfo, C. D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.997404 · Cited by 3

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC) Treatment: Quo Vadis?

Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126309 · Cited by 3

First-Line Treatment of Driver-Negative Non–Small Cell Lung Cancer

Kim, S. Y., & Gettinger, S. N. (2023) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2023.02.008 · Cited by 2

Evaluation of the Prognostic Impact of SP263-Evaluated PD-L1 Expression in Patients with Stage III Non-Small Cell Lung Cancer (NSLC) Treated with Radio-Chemotherapy

Wagner, J. N., Roeper, J., Heukamp, L. C., Falk, M., Willborn, K., & Griesinger, F. (2024) · Biomedicines · doi:10.3390/biomedicines12030688 · Cited by 2

First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials

Chen, W., Liu, H., Li, Y. H., Xue, W., Fan, S., Sun, J., Liu, S., Liu, Y., & Zhang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1365255 · Cited by 2

Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential

Jiang, D., Yoou, M., Cho, S., & Choi, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104497 · Cited by 2

Quality of Life of Lung Cancer Patients with Immune-Related Endocrinopathies During Immunotherapy: A Prospective Study Based on the EORTC QLQ-C30 and QLQ-LC13 Questionnaires in Romania

Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Anghel, A.-V., Bobolocu, M.-A., Zamfir, A., Lișcu, H.-D., Ionescu, A.-I., & Badiu, C. (2025) · Current Oncology · doi:10.3390/curroncol32060332 · Cited by 2

Real‐World Survival Outcomes of Patients With High PD‐L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy

Cheng, J., McKay, C., Bray, V., Yip, P. Y., Tognela, A., & Kok, P. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14205 · Cited by 2

Comparative efficacy of first-line therapies for PD-L1-negative advanced NSCLC: A network meta-analysis with reconstructed survival curves

Ma, J.-T., Yang, M., Zhang, S., Huang, L., Sun, L., & Han, C. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104831 · Cited by 2

Quality of life results and survival outcomes in trials of immunotherapy in advanced cancers: A systematic review and meta-research study

Avanzo, A., Salomone, F., Maïo, M. D., D’Ambrosio, S., Vitale, F., Viggiano, A., Liguori, L., Isernia, M. C., Russo, A., Longo, L., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104952 · Cited by 2

Long-term impact of COVID-19 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter cohort study during Omicron pandemic

Zhang, Y., Li, Y., Zhang, Y., Zhang, T., Li, M., Xin, Y., Wang, T. A., Feng, X., Xu, R., Xia, W., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11544-8 · Cited by 2

Deciphering macrophage heterogeneity and factors driving M2 polarization in lung adenocarcinoma through single-cell RNA sequencing

Sheng, M., Yu, B., Wang, Q., Xiao, Y., Ling, M., & Wu, X. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02172-3 · Cited by 2

Prognostic value of patient-reported outcomes for survival in patients with advanced lung cancer receiving immune checkpoint inhibitors

Gandara, D. R., Gogishvili, M., Sezer, A., Makharadze, T., Gümüş, M., Zhu, C., Yan, E. W. C., Gullo, G., Rietschel, P., & Quek, R. G. W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1640595 · Cited by 2

Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non–Small Cell Lung Cancer a Systemic Review and Meta-analysis

Choucair, K., Jang, H., Jalal, S. I., Hadid, T. H., Uprety, D., Kim, S., & Mamdani, H. M. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.10.014 · Cited by 2

Systemic therapy of nonsmall cell lung cancer: breakthroughs during the last five decades

Pirker, R., & Zhou, C. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001201 · Cited by 2

Squamous Non-Small Cell Lung Cancer: Current and Emerging Treatment Options

Paik, P. K., Zhang, J., West, H., & Riess, J. W. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.10.001 · Cited by 2

In vitro models to mimic tumor endothelial cell-mediated immune cell reprogramming in lung adenocarcinoma

Krejbich, M., Navarro, E., Fresquet, J., Cotinat, M., Isen, V., Perdrieau, H., Forest, V. F., Doméné, A., Delaunay, T., Awada, H., et al. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03576-4 · Cited by 2

COVID-19 and Lung Cancer Interactions: A Literature Review

László, S.-A., Ianoși, E. S., Văsieșiu, A.-M., Szathmáry, M., Ianoși, M. B., Rachiș, D.-L., Nistor, G., & Jimborean, G. (2025) · Medical Sciences · doi:10.3390/medsci13040295 · Cited by 2

Choice of fixative affects programmed death‐ligand 1 expression in cell blocks from pleural effusions with metastatic pulmonary adenocarcinoma

Mansour, M. S. I., Pettersson, L., Pedersen, R., Mager, U., Hejny, K., Kronqvist, F., Aronsson, A., Seidal, T., Akyürek, L. M., & Kholová, I. (2026) · Cancer Cytopathology · doi:10.1002/cncy.70078 · Cited by 2

Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1–high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part 1

Naidoo, J., Peters, S., Runglodvatana, Y., Li, J. Y.-C., Fong, C. H., Ho, G. F., How, S. H., Juengsamarn, J., Graham, J. R., Marina, N. M., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109316 · Cited by 2

Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy

Gandara, D. R., Gümüş, M., Kilickap, S., Sezer, A., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Yan, E. W. C., Jia, X., Kim, E., et al. (2026) · Cancer · doi:10.1002/cncr.70339 · Cited by 2

Efficacy of first-line immune checkpoint inhibitors in advanced non-small-cell lung cancer with or without brain metastases: a systematic review and network meta-analysis

Luo, J., Han, M., Sima, M., Cui, Y., Yu, Z., Dong, C., Ma, K., & Yue, D. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1809450 · Cited by 2

Circulating low-density neutrophils as biomarkers of resistance to first-line anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer

Castro, N., Labiano, I., Martínez-Aguillo, M., Huerta, A. E., Morilla, I., Teijeira, L., Serrano, D., Caseda, I., Lecumberri, A., Amat, I., et al. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102755 · Cited by 2

Immune Checkpoint-Based Therapies in Colorectal Cancer—Current Approaches and Future Perspectives

Nakielska, K., Plewka, J., & Lenart, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104628 · Cited by 2

Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies

Hidalgo-Filho, C. M., Santo, V., Gariazzo, E., Aldea, M. D., Pecci, F., Danlos, F., Junior, G. D. C., & Ricciuti, B. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03026 · Cited by 2

Immuntherapie des nichtkleinzelligen Lungenkarzinoms (NSCLC)

Frost, N., & Reck, M. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01363-3 · Cited by 2

Cox Proportional Hazard Ratios Overestimate Survival Benefit of Immune Checkpoint Inhibitors: Cox-TEL Adjustment and Meta-Analyses of Programmed Death-Ligand 1 Expression and Immune Checkpoint Inhibitor Survival Benefit

Lin, E. P.-Y., Hsu, C., Chiou, J.-F., Berry, L. D., Horn, L., Bunn, P. A., Yang, J. C., Yang, P., Adjei, A. A., & Shyr, Y. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.08.010 · Cited by 2

Association of CTLA4 and PD-L1 immunohistchemical expression with various clinicopathological parameters and survival in non–small-cell lung cancer

Amer, B. S., Amer, R., Awad, R., Darwish, S., & Bedeer, A. E. (2022) · International Journal of Cancer and Biomedical Research · doi:10.21608/jcbr.2022.168536.1282 · Cited by 2

Immunotherapy for Lung Cancer

KARADURMUŞ, N., Akyürek, N., Aydıner, A., Savaş, R., Sönmez, Ö. S., ŞENDUR, M. A. N., Oyan, B., Yalman, D., Yilmaz, M. U., Yılmaz, Ü., et al. (2023) · Journal of Oncological Sciences · doi:10.37047/jos.2022-92712 · Cited by 2

What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review

Agostara, A. G., Roazzi, L., Villa, F., Romanò, R., Piscazzi, D., Martinelli, F., Ciarlo, G., Oresti, S., Travaglini, F., Marando, A., et al. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2268509 · Cited by 2

Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer

Lang, Y., Lin, Y., Deng, M., & Liu, X. (2024) · BMC Cancer · doi:10.1186/s12885-024-11992-6 · Cited by 2

Use of Different Anti-PD-1 Checkpoint Combination Strategies for First-Line Advanced NSCLC Treatment—The Experience of Ion Chiricuță Oncology Institute

Preda, A.-C., Ciuleanu, T., Todor, N., Vlad, C. I., Iancu, D. I., Mocan, C., Bandi-Vasilica, M., Albu, F., Irina, T. B., Hapca, M. C., et al. (2024) · Cancers · doi:10.3390/cancers16112022 · Cited by 2

Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database

Cabart, M., Mourey, L., Pasquier, D., Schneider, S., Léna, H., Girard, N., CHOUAID, C., Schött, R., Hiret, S., Debieuvre, D., et al. (2024) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2024.101819 · Cited by 2

Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature

Pușcașu, A., Moinard‐Butot, F., Nannini, S., Fischbach, C., Schött, R., & Bender, L. (2024) · Cancers · doi:10.3390/cancers16173105 · Cited by 2

Comprehensive analysis of genomic alterations and novel prognostic biomarkers, and establishment of prediction models of metastasis in metastatic non-small cell lung cancer

Wang, K., Ye, M., Mo, Z., Huang, X., Li, Y., & Wei, S. (2024) · Journal of Cancer · doi:10.7150/jca.97070 · Cited by 2

Immuno-oncological Challenges and Chemoresistance in Veterinary Medicine: Probiotics as a New Strategic Tool

Nisar, M. F., Yan, T., Cai, Y., & Wan, C. C. (2025) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-025-10468-8 · Cited by 2

Immunotherapy in advanced non-small cell lung cancer: What to do for the ‘Invisible’ patients after IPSOS trial results?

Gridelli, C., Attili, I., Bennati, C., Bironzo, P., Bria, E., Cortinovis, D. L., Parra, H. J. S., & de Marinis, F. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108482 · Cited by 2

Cemiplimab in the treatment of metastatic basal cell carcinoma

Bapna, M., & Ruiz, E. S. (2025) · Future Oncology · doi:10.1080/14796694.2025.2511568 · Cited by 2

Costs of Extended Use of the Immune Check Point Inhibitors in 1st-line Non-Small Cell Lung Cancer

Guirgis, H. M. (2021) · Journal of Clinical and Medical Research · doi:10.37191/mapsci-2582-4333-3(5)-086 · Cited by 2

Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study

Quaquarini, E., Sottotetti, F., Agustoni, F., Pozzi, E., Malovini, A. L., Teragni, C. M., Palumbo, R., Saltalamacchia, G., Tagliaferri, B., Balletti, E., et al. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050679 · Cited by 2

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial

Clarke, J. M., Gu, L., Wang, X. F., Stinchcombe, T. E., Stevenson, M. M., Ramalingam, S., Shariff, A. I., Garst, J. L., Nixon, A. B., Antonia, S. J., et al. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100337 · Cited by 2

Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers

Mohanty, S. K., Mishra, S. K., Amin, M. B., Agaimy, A., & Fuchs, F. S. (2023) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000395 · Cited by 3

Comprehensive overview of biomarkers to predict response to immune checkpoint therapy in lung cancer

Jain, K. M., Mehra, D., Ganguly, N. K., Rana, R., Ganguly, S., & Aggarwal, S. (2023) · Current Medicine Research and Practice · doi:10.4103/cmrp.cmrp_78_23 · Cited by 2

Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC

Wu, W., Guo, J., He, L., Deng, Q., & Huang, X. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1390343 · Cited by 2

Jointly Modeling Time‐To‐Event and Longitudinal Data With Individual‐Specific Change Points: A Case Study in Modeling Tumor Burden

Alt, E. M., Qu, Y., Damone, E., Liu, J., Wang, C., & Ibrahim, J. G. (2025) · Statistics in Medicine · doi:10.1002/sim.70021 · Cited by 2

Zielgerichtete Therapie des nichtkleinzelligen Lungenkarzinoms

Scheffler, M., Michels, S. Y. F., & Nogová, L. (2022) · Die Innere Medizin · doi:10.1007/s00108-022-01372-2 · Cited by 2

Cemiplimab (Libtayo)

CADTH (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.433 · Cited by 2

Immune Checkpoint Inhibitors - New Insights and Recent Progress

Raza, A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100958 · Cited by 2

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Chen, C., Lin, C., Tsai, J., Lin, C., Chang, C., Yen, Y., Tseng, Y., Su, P., & Lin, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1238876 · Cited by 2

The effect of gender on the clinical outcome of PD-1/PD-L1 inhibitor in advanced lung cancer patients

Wu, B., Sun, C. M., Sun, X., & Li, X. (2023) · Medicine · doi:10.1097/md.0000000000034849 · Cited by 2

Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials

Meyers, D. E., Rittberg, R., Dawe, D. E., & Banerji, S. O. (2024) · Current Oncology · doi:10.3390/curroncol31090407 · Cited by 2

Pulmonology (Lung)

Verma, D., Faiz, S. A., Shannon, V. R., Altan, M., & Sheshadri, A. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_14 · Cited by 2

Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures

Moreira, A. L., & Sabari, J. K. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.01.010 · Cited by 2

Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Lin, H., Ma, C., Zhong, A., Zang, H., Chen, W., Li, L., Le, Y., & Xie, Q. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207326666230808112656 · Cited by 1

Advancements in non-small cell lung cancer treatment: from early to advanced stages

Płużański, A., & Piórek, A. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.100477 · Cited by 1

Immunotherapy outcomes in non-small cell lung cancer according to a gender perspective

Vavalà, T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.09.004 · Cited by 1

Arthralgia in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis

Nishimura, Y., Estaris, J., Koseki, M., Elias, E., Chesta, F., Takaoka, K., Shao, T. H., Horita, N., & Fujiwara, Y. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2501519 · Cited by 1

Indoleamine 2,3-dioxygenase-1 expression in non-small-cell lung cancer: analyses of prevalence, clinical correlations and prognostic impact in 2 large patient cohorts

Agustoni, F., Yu, H., Ellison, K. E., Smith, D. E., Mitchell, P. L. R., Rivalland, G., Dziadziuszko, R., Gao, D., Ren, S., Rivard, C. J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1586782 · Cited by 1

Peripheral blood cells as prognostic markers in patients with advanced non-small cell lung cancer treated with cemiplimab as monotherapy or in combination with chemotherapy

Acosta, R. J., McIntyre, D., Murray, J. C., Anagnostou, V., Brahmer, J. R., Meisel, A., Sezer, A., Gogishvili, M., Melkadze, T., Baramidze, A., et al. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100959 · Cited by 1

Regulatory polymorphisms of MSH6, MSH2, FBXO11, and PPP1R21 genes affect survival of patients with immunotherapy-treated lung cancer

Esposito, M., Noci, S., Minnai, F., Camboni, T., Mangano, E., Gariboldi, M., Frullanti, E., Bareggi, C., Collovà, E., Girelli, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011526 · Cited by 1

Durvalumab in Patients With Treatment-Naive Stage IV NSCLC With an ECOG Performance Status of 2 to 3 and High PD-L1 Tumor Expression (IFCT-1802 SAVIMMUNE): A Multicenter Phase 2 Trial

Gounant, V., Greillier, L., Mascaux, C., Pinquie, F., Carmier, D., Moreau, L., Roch, B., Debieuvre, D., Dhalluin, X., Leprieur, E. G., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100908 · Cited by 1

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer

Xue, X., Loop, M. S., Johnson, B., Ngorsuraches, S., Zheng, J., & Qian, J. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.11.1123 · Cited by 1

Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US

Schoenfeld, A. J., Hu, C., Rajaram, R., Feliciano, J. L., Chandran, U., Wong, C., Kalsekar, I. D., Wang, T., Huang, Q., & Hasan, A. (2025) · Future Oncology · doi:10.1080/14796694.2025.2592721 · Cited by 1

When cancer treatment affects the lungs: a clinical overview on pulmonary toxicity induced by new cancer drugs

Komninos, D., Psarros, E., Theochari, E., Tsirikos, G., Sampsonas, F., & Tzouvelekis, A. (2026) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2026.2631816 · Cited by 1

Cost-effectiveness analysis of immune checkpoint inhibitors versus platinum-based doublet chemotherapy in the first-line treatment of advanced non-small-cell lung cancer with High PD-L1 expression in Japan

Nusawat, C., Sato, S., Taniguchi, J., Kimura, Y., & Yasunaga, H. (2026) · The European Journal of Health Economics · doi:10.1007/s10198-026-01912-9 · Cited by 1

Safety and effectiveness of immune checkpoint inhibitors in older adults with metastatic non-small cell lung cancer and pre-existing autoimmune disease – A SEER-Medicare study

Gohil, S., Chen, H., Lewis, W. E., Trivedi, M. V., Aparasu, R. R., & Johnson, M. L. (2026) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2026.102971 · Cited by 1

Treatment switching in evidence synthesis in oncology: A systematic review of current meta-analytical practices

Metcalfe, R., Vuong, Q., Yan, Y., Gorst‐Rasmussen, A., Remiro‐Azócar, A., Morga, A., Keene, O. N., Dron, L., & Park, J. J. H. (2026) · Research Synthesis Methods · doi:10.1017/rsm.2026.10076 · Cited by 2

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC

Dugage, M. R., Yurchenko, A., Nikolaev, S. I., Nabet, B. Y., Corgnac, S., Anquetil, C., Srivastava, M. K., Gayevskiy, V., McNally, V. A., Mezquita, L., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2026-014991 · Cited by 1

Current Roles of Neoadjuvant and Perioperative Immunotherapy in Non–Small Cell Lung Cancer

Fankuchen, O., Punekar, S. R., & Velcheti, V. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01265 · Cited by 1

First-line management of advanced non-small-cell lung cancer: can we do better?

CHOUAID, C., Monnet, I., & Auliac, J. B. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-200 · Cited by 1

Role of miRNAs as epigenetic regulators of immune checkpoints in lung cancer immunity

Cánovas‐Cervera, I., Nácher-Sendra, E., Suay, G., Lahoz, A., García‐Giménez, J. L., & Mena, S. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.002 · Cited by 1

Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review

Zhao, X., Wang, X., Liu, S., Cheng, P., Chen, J., & Liu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548452 · Cited by 1

Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non–Small Cell Lung Cancer Management With Cemiplimab

Perez, J., Kerr, K. M., Baker, B., Fang, F., Li, J. Z., McDonald, J., Li, S., Gao, B., Pouliot, J., Seebach, F. A., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00177 · Cited by 1

Cemiplimab in Japanese patients with advanced non-small cell lung cancer

Sato, Y., Tani, Y., Ishii, H., Katakura, S., Oki, M., Watanabe, Y., Yokoyama, T., Naoki, K., Pouliot, J., Kaul, M., et al. (2025) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyaf160 · Cited by 1

Unlocking the Immune System: Advances in Next-generation Immunotherapy for Lung Cancer

Choudhary, F., Safdar, A., Abdin, M. Z., & Farooqi, H. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575415429251007093531 · Cited by 1

Efficacy and safety comparisons of PD-1 versus PD-L1 inhibitors in patients with solid cancer: a systematic review and meta-analysis

Yu, J., Zhou, Q., Wang, G., Shi, S., Wang, H., Yang, J., Sun, X., Li, J., Shi, Y., Wang, J., et al. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.01.004 · Cited by 1

Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study

Mıldanoğlu, M. M., Yücel, M. H., Delipoyraz, E. E., Sünger, E., Özçelik, H., FİDAN, S., Terzioglu, C., Muğlu, H., Hamdard, J., Demirel, B. Ç., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062406 · Cited by 1

AdipoR1–AMPK axis suppresses breast cancer across molecular subtypes via multimodal cell death pathways, including ferroptosis and apoptosis

Sato, S., Yamanaka, T., Komori, Y., Ishida, M., Nakamura, Y., Yamashita, T., & Miyagi, Y. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08583-7 · Cited by 1

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

Özgüroğlu, M., Kılıçkap, S., Sezer, A., Gümüş, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., Ho, G. F., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00329-7 · Cited by 118

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Gogishvili, M., Melkadze, T., Makharadze, T., Giorgadze, D., Dvorkin, M. V., Penkov, K., Лактионов, К. К., Nemsadze, G., Nechaeva, M., Rozhkova, I., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01977-y · Cited by 319

Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1

Kılıçkap, S., Baramidze, A., Sezer, A., Özgüroğlu, M., Gumus, M., Bondarenko, I., Gogishvili, M., Nechaeva, M., Schenker, M., Çiçin, İ., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.03.033 · Cited by 39

119TiP An observational study to assess the effectiveness and safety of cemiplimab in patients with advanced non-small cell lung cancer (NSCLC) in routine clinical practice within Europe (CEMI-LUNG)

Gessner, C., Griesinger, F., Shah, R., Talbot, T., Venkateshan, S., Shankar, A. K. V., Seluzhytsky, A., & Marsden, D. M. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100223 · Cited by 3

P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1

Gümüs, M., Kılıçkap, S., Sezer, A., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., He, X., Gullo, G., Rietschel, P., & Quek, R. G. W. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.09.556